5. Summary of adverse events experienced.

Study and drug	Privitera 2003				SANAD A 2007
	TPM 100	TPM 200	CBZ	Total	TPM	CBZ	Total
Number experiencing adverse events	120	114	111	345	283	260	543
Number of adverse events	1063	1035	970	3068	2503	1339	3842
Number of adverse events per person (range)	1 to 40	1 to 30	1 to 37	NA	1 to 35	1 to 37	NA
Number of drug related adverse eventsa	578	613	537	1728	NA	NA	NA
Number of adverse events requiring action/treatment changeb	76	90	72	238	705	529	1234
Number of participants needing a treatment change/dose changeb	27	31	32	90	185	173	358

CBZ = carbamazepine, NA = not available, TPM = topiramate, TPM 100 = topiramate 100 mg/day, TPM 200 = topiramate 200 mg/day (Privitera 2003)

^aDefined as events which are 'very likely,' 'probably' or 'possibly' related in Privitera 2003. Not stated if events were drug‐related in SANAD A 2007.
 ^bInformation given only for drug discontinuation in Privitera 2003. Information on drug discontinuation and dose change in SANAD A 2007.